Genetic Polymorphisms of 5-HT Receptors and Antipsychotic-Induced Metabolic Dysfunction in Patients with Schizophrenia
- PMID: 33807811
- PMCID: PMC7999828
- DOI: 10.3390/jpm11030181
Genetic Polymorphisms of 5-HT Receptors and Antipsychotic-Induced Metabolic Dysfunction in Patients with Schizophrenia
Abstract
Background: Antipsychotic-induced metabolic syndrome (MetS) is a multifactorial disease with a genetic predisposition. Serotonin and its receptors are involved in antipsychotic-drug-induced metabolic disorders. The present study investigated the association of nine polymorphisms in the four 5-hydroxytryptamine receptor (HTR) genes HTR1A, HTR2A, HTR3A, and HTR2C and the gene encoding for the serotonin transporter SLC6A4 with MetS in patients with schizophrenia.
Methods: A set of nine single-nucleotide polymorphisms of genes of the serotonergic system was investigated in a population of 475 patients from several Siberian regions (Russia) with a clinical diagnosis of schizophrenia. Genotyping was performed and the results were analyzed using chi-square tests.
Results: Polymorphic variant rs521018 (HTR2C) was associated with higher body mass index in patients receiving long-term antipsychotic therapy, but not with drug-induced metabolic syndrome. Rs1150226 (HTR3A) was also associated but did not meet Hardy-Weinberg equilibrium.
Conclusions: Our results indicate that allelic variants of HTR2C genes may have consequences on metabolic parameters. MetS may have too complex a mechanistic background to be studied without dissecting the syndrome into its individual (causal) components.
Keywords: antipsychotics; body mass index; genes; metabolic syndrome; pharmacogenetics; schizophrenia; serotonin; weight gain.
Conflict of interest statement
The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
Similar articles
-
5-Hydroxytryptamine Receptors and Tardive Dyskinesia in Schizophrenia.Front Mol Neurosci. 2020 Apr 24;13:63. doi: 10.3389/fnmol.2020.00063. eCollection 2020. Front Mol Neurosci. 2020. PMID: 32390801 Free PMC article.
-
Association between HTR2C polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychotics.Schizophr Res. 2011 Feb;125(2-3):179-86. doi: 10.1016/j.schres.2010.11.030. Epub 2010 Dec 23. Schizophr Res. 2011. PMID: 21185157
-
Identification of 5-hydroxytryptamine receptor gene polymorphisms modulating hyperprolactinaemia in antipsychotic drug-treated patients with schizophrenia.World J Biol Psychiatry. 2017 Apr;18(3):239-246. doi: 10.1080/15622975.2016.1224926. Epub 2016 Sep 22. World J Biol Psychiatry. 2017. PMID: 27654063
-
The Progress and Pitfalls of Pharmacogenetics-Based Precision Medicine in Schizophrenia Spectrum Disorders: A Systematic Review and Meta-Analysis.J Pers Med. 2023 Mar 4;13(3):471. doi: 10.3390/jpm13030471. J Pers Med. 2023. PMID: 36983653 Free PMC article. Review.
-
Pharmacogenetics and the serotonin system: initial studies and future directions.Eur J Pharmacol. 2000 Dec 27;410(2-3):165-181. doi: 10.1016/s0014-2999(00)00814-1. Eur J Pharmacol. 2000. PMID: 11134668 Review.
Cited by
-
Efficacy and safety of blonanserin versus risperidone in the treatment of schizophrenia: a systematic review and meta-analysis of randomized controlled trials.BMC Psychiatry. 2023 Oct 11;23(1):740. doi: 10.1186/s12888-023-05240-7. BMC Psychiatry. 2023. PMID: 37821875 Free PMC article.
-
The Gender-Specific Association of DRD2 Polymorphism with Metabolic Syndrome in Patients with Schizophrenia.Genes (Basel). 2022 Jul 23;13(8):1312. doi: 10.3390/genes13081312. Genes (Basel). 2022. PMID: 35893053 Free PMC article.
-
Metabolic Hormones in Schizophrenia Patients with Antipsychotic-Induced Metabolic Syndrome.J Pers Med. 2022 Oct 5;12(10):1655. doi: 10.3390/jpm12101655. J Pers Med. 2022. PMID: 36294794 Free PMC article.
-
Psychoneurobiology Research and Personalized Treatment of Schizophrenia.J Pers Med. 2021 Dec 7;11(12):1319. doi: 10.3390/jpm11121319. J Pers Med. 2021. PMID: 34945791 Free PMC article.
-
Safety and Effectiveness of Blonanserin in Chinese Patients with Schizophrenia: An Interim Analysis of a 12-Week Open-Label Prospective Multi-Center Post-marketing Surveillance.Front Psychiatry. 2022 Aug 18;13:935769. doi: 10.3389/fpsyt.2022.935769. eCollection 2022. Front Psychiatry. 2022. PMID: 36061293 Free PMC article.
References
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources